This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration. We also talk about a report from the World Health Organization on tobacco use worldwide. Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor.

Coverage of stories discussed this week on ascopost.com:

Erdafitinib in FGFR Altered Advanced Urothelial Carcinoma

WHO Releases Report on the Global Tobacco Epidemic

FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor